Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

NCT01024231 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: BMS-936558 (MDX1106-04)
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]